SMS Pharmaceuticals Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tdx7q5bktme17eg1n5cvcezl.pdf

Key Takeaways


ARV: The Q4 Collapse & Recovery Bet

Potluri: "However, we firmly believe that second half of FY22 was a one-off in terms of ARV demand, and the issues are transient in nature."

Ibuprofen: The Ramp, The Risk & The Revenue

Potluri: "We believe that the demand and pricing of Ibuprofen has almost bottomed out and going forward we should expect a significant rebound."

Sitagliptin & The Patent-Expiry Pipeline

Potluri: "post-launch, the amount of market share that you will be able to capture actually decides the fate of the product going forward."

COVID-19 Opportunistic Products

Potluri: "So, again, see some of these products which are opportunistic in nature so it is very difficult to predict, because you suddenly could expect an unexpected wave and suddenly the wave could, suddenly gather some good momentum and the product sales could go high."

Margins, Costs & The Industry Squeeze

Potluri: "But our EBITDA target is definitely will be above 22%."

Associate Company: VKT Pharma


Guidance & Commitments

CommitmentSpecificsTimeline
ARV revenue recoveryReturn to earlier levels based on bids already awardedBy end of H1 FY23
Ibuprofen capacity utilizationReach 80–85% of installed capacityBy end of FY23
Ibuprofen CEP approvalCEP approval expectedNext 1–2 months
Ibuprofen capacity expansionExpand to 600–700 tonnes via CAPEX or debottleneckingBy end of FY23
FY23 revenue growthMinimum 25% growth over FY22FY23
EBITDA marginAbove 22%FY23 (implied)
Gross margin rangeMaintain 40–45%Going forward
DebtNo anticipated increase; normal expenditure from internal accrualsNext 1–2 years
Major CAPEXNo major expansion planned; consolidate existing productsNext 2 years

Key Metrics

MetricQ4 FY22
Consolidated revenue (FY22)₹519.9 cr
Gross margin (FY22)~48%, up from ~40% in FY21
EBITDA margin targetAbove 22% going forward
Gross margin guidance40% to 45% range going forward
FY23 revenue growth targetMinimum 25% increase over FY22
ARV revenue contribution~6–7% of revenue, down from ~40–45% (per an analyst's statement)
ARV revenue (9M FY22)More than ₹200 cr in nine months; Q4 was hardly ₹6 cr (per an analyst's statement)
Ibuprofen installed capacity500 metric tonnes per month
Ibuprofen capacity utilization20%, up from 10% two months prior
Ibuprofen capacity utilization expected by FY23 end80% to 85%
Ibuprofen peak revenue expectation₹450 cr to ₹500 cr at full-scale operations
Ibuprofen current priceAround $9 range
Ibuprofen industry growth rateLess than 5%
Sitagliptin API market size estimate₹400 cr to ₹500 cr at peak (Europe; U.S. expiry in 2024)
JV with Chemo revenue contributionAround 5% to 8% of sales
Interest costsIncreased 69% YoY on yearly basis (per an analyst's statement)
CAPEX spent last year₹200 cr, mainly on Ibuprofen
VKT Pharma ANDA approvalsSix ANDAs approved end February 2022